<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Epoetin alfa</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Epoetin_alfa">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Epoetin alfa</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Epoetin alfa</b> is a human erythropoietin produced in cell culture using recombinant DNA technology.<span class="mw-ref" id="cite_ref-isbn0-415-26368-9_1-0"><a href="#cite_note-isbn0-415-26368-9-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.</p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Epoetin alfa</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ɛ</span><span>ˈ</span><span>p</span><span>oʊ</span><span>.</span><span>ɪ</span><span>t</span><span>ɪ</span><span>n</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Epogen, Retacrit</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>epoetin alfa-epbx</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/epoetin_alfa.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/epoetin_alfa.html'" tppabs="https://www.drugs.com/monograph/epoetin_alfa.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a692034.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a692034.html'" tppabs="https://medlineplus.gov/druginfo/meds/a692034.html" class="external text external">a692034</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Epoetin+alfa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Epoetin+alfa'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Epoetin+alfa" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epoetin_alfa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epoetin_alfa'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epoetin_alfa" class="external text external">Epoetin_alfa</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">

<ul><li>Unknown</li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>IV or subcutaneous</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>B03XA01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=B03XA01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=B03XA01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=B03XA01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=11096-26-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=11096-26-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=11096-26-7" class="external text external">11096-26-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00016'" tppabs="https://www.drugbank.ca/drugs/DB00016" class="external text external">DB00016</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=64FS3BFH5W  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=64FS3BFH5W'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=64FS3BFH5W" class="external text external">64FS3BFH5W</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201565  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201565'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201565" class="external text external">ChEMBL1201565</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>815</sub><span>H</span><sub>1317</sub><span>N</span><sub>233</sub><span>O</span><sub>241</sub><span>S</span><sub>5</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">18<span style="margin-left:.25em;">396</span>.19</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=476993050&page2=Epoetin+alfa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=476993050&page2=Epoetin+alfa'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=476993050&page2=Epoetin+alfa" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>Epoetin is manufactured and marketed by Amgen under the trade name <b>Epogen</b>. Johnson &amp; Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Products, LP), sells the same drug under the name Procrit, pursuant to a product license agreement. The average cost per  patient in the U.S. was $8,447 in 2009.<span class="mw-ref" id="cite_ref-pmid19828525_2-0"><a href="#cite_note-pmid19828525-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span>  <a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a> (rINN) <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>d</span><span>ɑːr</span><span>b</span><span>ə</span><span>ˈ</span><span>p</span><span>ɔɪ</span><span>t</span><span>ɪ</span><span>n</span></span>/</span></span> is a glycosylation analog of erythropoietin containing two additional N-linked carbohydrate chains,<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> also manufactured and marketed by Amgen, with a trade name of Aranesp. The FDA warnings and safety precautions for Procrit, Epogen and Aranesp are identical.</p>

<p>For several years, epoetin alfa has accounted for the single greatest drug expenditure paid by the U.S. Medicare system; in 2010, the program paid $2 billion for the drug.<span class="mw-ref" id="cite_ref-GAO_4-0"><a href="#cite_note-GAO-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-JAMA_5-0"><a href="#cite_note-JAMA-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Raising hemoglobin levels has been found in some studies to be associated with higher risks of thrombotic events, strokes and death.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    

<p>Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anemia resulting from chronic kidney disease and myelodysplasia, from the treatment of cancer (chemotherapy and radiation).</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Anemia_caused_by_kidney_disease">Anemia caused by kidney disease</h3></summary>
    

<p>For patients who require dialysis or have chronic kidney disease, iron should be given with erythropoietin, depending on some laboratory parameters such as ferritin and transferrin saturation.<span class="mw-ref" id="cite_ref-pmid8914038_7-0"><a href="#cite_note-pmid8914038-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Dialysis patients in the U.S. are most often given Epogen; other brands of epoetin may be used in other countries.</p>

<p>Erythropoietin is also used to treat anemia in people with chronic kidney disease who are not on dialysis (those in Stage 3 or 4 disease and those living with a kidney transplant). There are two types of erythropoietin for people with anemia due to chronic kidney disease (not on dialysis).</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Anemia_caused_by_cancer">Anemia caused by cancer</h3></summary>
    
<p>In March 2008, a panel of advisers for the U.S. Food and Drug Administration (FDA) supported keeping erythropoiesis-stimulating agents (ESAs) produced by Amgen and Johnson &amp; Johnson on the market for use in cancer patients. The FDA has focused its concern on study results from some clinical trials showing an increased risk of death and tumor growth in chemotherapy patients taking the anti-anemia drugs.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Anemia_in_critically_ill_people">Anemia in critically ill people</h3></summary>
    

<p>Erythropoietin is used to treat people with anemia resulting from critical illness.</p>

<p>In a randomized controlled trial,<span class="mw-ref" id="cite_ref-pmid17804841_8-0"><a href="#cite_note-pmid17804841-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> erythropoietin was shown to not change the number of blood transfusions required by critically ill patients. A surprising finding in this study was a small mortality reduction in patients receiving erythropoietin. This result was statistically significant after 29 days but not at 140 days. The mortality difference was most marked in patients admitted to the ICU for trauma. The authors provide several hypotheses for potential etiologies of this reduced mortality, but, given the known increase in thrombosis and increased benefit in trauma patients as well as marginal nonsignificant benefit (adjusted hazard ratio of 0.9) in surgery patients, it could be speculated that some of the benefit might be secondary to the procoagulant effect of erythropoetin.  Regardless, this study suggests further research may be necessary to see which critical care patients, if any, might benefit from administration of erythropoeitin. Any benefit of erythropoetin use must be weighed against the increased likelihood of thrombosis, which has been demonstrated in numerous trials .</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Neurological_diseases">Neurological diseases</h3></summary>
    

<p>Erythropoietin has been hypothesized to be beneficial in treating certain neurological diseases such as schizophrenia and stroke.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Some research has suggested that erythropoietin improves the survival rate in children suffering from cerebral malaria, which is caused by the malaria parasite's blockage of blood vessels in the brain.<span class="mw-ref" id="cite_ref-pmid19008152_10-0"><a href="#cite_note-pmid19008152-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-pmid21044627_11-0"><a href="#cite_note-pmid21044627-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> However, the possibility that erythropoietin may be neuroprotective is inconsistent with the poor transport of the chemical into the brain<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> and the low levels of erythropoietin receptors expressed on neuronal cells.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Preterm_infants">Preterm infants</h3></summary>
    
<p>Infants born early often require transfusions with red blood cells and have low levels of erythropoietin. Erythropoietin has been studied as a treatment option to reduce anemia in preterm infants. Treating infants less than 8 days with erythropoietin old may slightly reduce the need for red blood cell transfusions, but increases the risk of retinopathy. Due to the limited clinical benefit and increased risk of retinopathy, early or late erythropoietin treatment is not recommended for preterm infants.<span class="mw-ref" id="cite_ref-:0_14-0"><a href="#cite_note-:0-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-:1_15-0"><a href="#cite_note-:1-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    

<p>Epoetin alfa is generally well tolerated. Common side effects include high blood pressure, headache, disabling cluster migraine (resistant to remedies), joint pain, and clotting at the injection site. Rare cases of stinging at the injection site, skin rash, and flu-like symptoms (joint and muscle pain) have occurred within a few hours following administration. More serious side effects, including allergic reactions, seizures and thrombotic events (e.g., heart attacks, strokes, and pulmonary embolism) rarely occur. Chronic self-administration of the drug has been shown to cause increases in blood hemoglobin and hematocrit to abnormally high levels, resulting in dyspnea and abdominal pain.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>Erythropoietin is associated with an increased risk of adverse cardiovascular complications in patients with kidney disease if it is used to target an increase of hemoglobin levels above 13.0 g/dl.<span class="mw-ref" id="cite_ref-pmid17108342_17-0"><a href="#cite_note-pmid17108342-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Early treatment (before an infant is 8 days old) with erythropoietin correlated with an increase in the risk of retinopathy of prematurity in premature and anemic infants, raising concern that the angiogenic actions of erythropoietin may exacerbate retinopathy.<span class="mw-ref" id="cite_ref-:0_14-1"><a href="#cite_note-:0-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-:1_15-1"><a href="#cite_note-:1-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Since anemia itself increases the risk of retinopathy, the correlation with erythropoietin treatment may be incidental.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Safety_advisories_in_anemic_cancer_patients">Safety advisories in anemic cancer patients</h3></summary>
    

<p>Amgen sent a "dear doctor" letter in January 2007 that highlighted results from a recent anemia of cancer trial, and warned doctors to consider use in that off-label indication with caution.</p>

<p>Amgen advised the U.S. Food and Drug Administration (FDA) regarding the results of the DAHANCA 10 clinical trial. The DAHANCA 10 data monitoring committee found that three-year loco-regional cancer control in subjects treated with Aranesp was significantly worse than for those not receiving Aranesp (p=0.01).</p>

<p>In response to these advisories, the FDA released a Public Health Advisory<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span>
on March 9, 2007, and a clinical alert<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> for doctors on February 16, 2007, about the use of erythropoeisis-stimulating agents (ESAs) such as epogen and <a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin" title="Darbepoetin" class="mw-redirect">darbepoetin</a>. The advisory recommended caution in using these agents in cancer patients receiving chemotherapy or off chemotherapy, and indicated a lack of clinical evidence to support improvements in quality of life or transfusion requirements in these settings.</p>

<p>In addition, on March 9, 2007, drug manufacturers agreed to new black box warnings about the safety of these drugs.</p>

<p>On March 22, 2007, a congressional inquiry into the safety of erythropoeitic growth factors was reported in the news media.  Manufacturers were asked to suspend drug rebate programs for physicians and to also suspend marketing the drugs to patients.</p>

<p>Several publications and FDA communications have increased the level of concern related to adverse effects of ESA therapy in selected groups. In a revised black box warning, the FDA notes significant risks, advising that ESAs should be used only in patients with cancer when treating anemia specifically caused by chemotherapy, and not for other causes of anemia. Further, the warning states that ESAs should be discontinued once the patient's chemotherapy course has been completed.<span class="mw-ref" id="cite_ref-urlMedWatch_-_2007_Safety_Information_Alerts_20-0"><a href="#cite_note-urlMedWatch_-_2007_Safety_Information_Alerts-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-urlwww.fda.gov__Procrit_21-0"><a href="#cite_note-urlwww.fda.gov__Procrit-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-urlwww.fda.gov__Aranesp_22-0"><a href="#cite_note-urlwww.fda.gov__Aranesp-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-urlInformation_on_Erythropoiesis_Stimulating_Agents_(ESA)_(marketed_as_Procrit,_Epogen,_and_Aranesp)_23-0"><a href="#cite_note-urlInformation_on_Erythropoiesis_Stimulating_Agents_(ESA)_(marketed_as_Procrit,_Epogen,_and_Aranesp)-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    

<p>Drug interactions with erythropoietin include:</p>
<ul><li><b>Major</b>: <a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">lenalidomide</a>—risk of thrombosis</li>
<li><b>Moderate</b>: <a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclosporine" title="Cyclosporine" class="mw-redirect">cyclosporine</a>—risk of high blood pressure may be greater in combination with EPO. EPO may lead to variability in blood levels of cyclosporine.</li>
<li><b>Minor</b>: ACE inhibitors may interfere with hematopoiesis by decreasing the synthesis of endogenous erythropoietin or decreasing bone marrow production of red blood cells.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    

<p>The publication of an editorial questioning the benefits of high-dose epoetin was canceled by the marketing branch of a journal after being accepted by the editorial branch highlighting concerns of conflict of interest in publishing.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>

<p>In 2011, author Kathleen Sharp published a book, <i>Blood Feud: The Man Who Blew the Whistle on One of the Deadliest Prescription Drugs Ever</i>,<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>
alleging drug maker Johnson &amp; Johnson encouraged doctors to prescribe epoetin in high doses, particularly for cancer patients, because this would increase sales by hundreds of millions of dollars.  Former sales representatives Mark Duxbury and Dean McClennan, claimed that the bulk of their business selling epoetin to hospitals and clinics was Medicare fraud, totaling <span style="white-space: nowrap">US$3</span><span class="nowrap"><span>&nbsp;</span></span>billion.<span class="mw-ref" id="cite_ref-cbs_27-0"><a href="#cite_note-cbs-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>In August 2007, Binocrit, Epoetin Alfa Hexal, and Abseamed were approved for use in the European Union.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Erythropoietin</li>
<li>Epoetin beta</li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li>Peginesatide</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-isbn0-415-26368-9-1"> <span id="mw-reference-text-cite_note-isbn0-415-26368-9-1" class="mw-reference-text"><cite id="CITEREFWalshSpada2005" class="citation book cs1">Walsh G, Spada S (2005). <a href="javascript:if(confirm('https://archive.org/details/directoryofappro00spad/page/39  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/directoryofappro00spad/page/39'" tppabs="https://archive.org/details/directoryofappro00spad/page/39" class="external text external">"Epogen/Procrit"</a>. <i>Directory of approved biopharmaceutical products</i>. Boca Raton: CRC Press. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/directoryofappro00spad/page/39  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/directoryofappro00spad/page/39'" tppabs="https://archive.org/details/directoryofappro00spad/page/39" class="external text external">39–41</a>. ISBN<span>&nbsp;</span><bdi>978-0-415-26368-9</bdi>.</cite></span></li><li id="cite_note-pmid19828525-2"> <span id="mw-reference-text-cite_note-pmid19828525-2" class="mw-reference-text"><cite id="CITEREFEngelbergKesselheimAvorn2009" class="citation journal cs1">Engelberg AB, Kesselheim AS, Avorn J (November 2009). "Balancing innovation, access, and profits--market exclusivity for biologics". <i>The New England Journal of Medicine</i>. <b>361</b> (20): 1917–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp0908496  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp0908496'" tppabs="https://doi.org/10.1056%2FNEJMp0908496" class="external text external">10.1056/NEJMp0908496</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19828525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19828525'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19828525" class="external text external">19828525</a>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFElliottLorenziniAsherAoki2003" class="citation journal cs1">Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L,  et al. (April 2003). "Enhancement of therapeutic protein in vivo activities through glycoengineering". <i>Nature Biotechnology</i>. <b>21</b> (4): 414–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnbt799  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnbt799'" tppabs="https://doi.org/10.1038%2Fnbt799" class="external text external">10.1038/nbt799</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12612588  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12612588'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12612588" class="external text external">12612588</a>.</cite></span></li><li id="cite_note-GAO-4"> <span id="mw-reference-text-cite_note-GAO-4" class="mw-reference-text"><cite class="citation cs2"><a href="javascript:if(confirm('http://www.gao.gov/assets/660/655608.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gao.gov/assets/660/655608.pdf'" tppabs="http://www.gao.gov/assets/660/655608.pdf" class="external text external">"Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives.<span>]</span> Medicare. Information on Highest-Expenditure Part B Drugs."</a> <span class="cs1-format">(PDF)</span>, <i>United States Government Accountability Office (GAO)</i>, 28 June 2013<span class="reference-accessdate">, retrieved <span class="nowrap">29 June</span> 2015</span></cite></span></li><li id="cite_note-JAMA-5"> <span id="mw-reference-text-cite_note-JAMA-5" class="mw-reference-text"><cite id="CITEREFMitka2013" class="citation cs2">Mitka, Mike (14 August 2013), "Capitol Health Call: High-Cost Drugs Account for Most of Medicare Part B Spending", <i>JAMA</i>, <b>310</b> (6): 572, doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.2013.192555  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.2013.192555'" tppabs="https://doi.org/10.1001%2Fjama.2013.192555" class="external text external">10.1001/jama.2013.192555</a></cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><a href="javascript:if(confirm('https://www.washingtonpost.com/business/economy/anemia-drug-made-billions-but-at-what-cost/2012/07/19/gJQAX5yqwW_print.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.washingtonpost.com/business/economy/anemia-drug-made-billions-but-at-what-cost/2012/07/19/gJQAX5yqwW_print.html'" tppabs="https://www.washingtonpost.com/business/economy/anemia-drug-made-billions-but-at-what-cost/2012/07/19/gJQAX5yqwW_print.html" class="external text external">Anemia drugs made billions, but at what cost?</a> By Peter Whoriskey, Washington Post, July 19, 2012</span></li><li id="cite_note-pmid8914038-7"> <span id="mw-reference-text-cite_note-pmid8914038-7" class="mw-reference-text"><cite id="CITEREFMacdougallTuckerThompsonTomson1996" class="citation journal cs1">Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (November 1996). "A randomized controlled study of iron supplementation in patients treated with erythropoietin". <i>Kidney International</i>. <b>50</b> (5): 1694–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fki.1996.487  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fki.1996.487'" tppabs="https://doi.org/10.1038%2Fki.1996.487" class="external text external">10.1038/ki.1996.487</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8914038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8914038'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8914038" class="external text external">8914038</a>.</cite></span></li><li id="cite_note-pmid17804841-8"> <span id="mw-reference-text-cite_note-pmid17804841-8" class="mw-reference-text"><cite id="CITEREFCorwinGettingerFabianMay2007" class="citation journal cs1">Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ (September 2007). "Efficacy and safety of epoetin alfa in critically ill patients". <i>The New England Journal of Medicine</i>. <b>357</b> (10): 965–76. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa071533  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa071533'" tppabs="https://doi.org/10.1056%2FNEJMoa071533" class="external text external">10.1056/NEJMoa071533</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17804841  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17804841'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17804841" class="external text external">17804841</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFEhrenreichDegnerMellerBrines2004" class="citation journal cs1">Ehrenreich H, Degner D, Meller J, Brines M, Béhé M, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, von Ahsen N, Maier W, Brück W, Rüther E, Cerami A, Becker W, Sirén AL (January 2004). <a href="javascript:if(confirm('https://web.archive.org/web/20120305202823/http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120305202823/http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf'" tppabs="https://web.archive.org/web/20120305202823/http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf" class="external text external">"Erythropoietin: a candidate compound for neuroprotection in schizophrenia"</a> <span class="cs1-format">(PDF)</span>. <i>Molecular Psychiatry</i>. <b>9</b> (1): 42–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.mp.4001442  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.mp.4001442'" tppabs="https://doi.org/10.1038%2Fsj.mp.4001442" class="external text external">10.1038/sj.mp.4001442</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14581931  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14581931'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14581931" class="external text external">14581931</a>. Archived from <a href="javascript:if(confirm('http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf'" tppabs="http://physiologie.univ-lyon1.fr/enseignement/coursLB/Ehrenreich2004.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2012-03-05.</cite></span></li><li id="cite_note-pmid19008152-10"> <span id="mw-reference-text-cite_note-pmid19008152-10" class="mw-reference-text"><cite id="CITEREFCasals-PascualIdroPicotRoberts2009" class="citation journal cs1">Casals-Pascual C, Idro R, Picot S, Roberts DJ, Newton CR (January 2009). "Can erythropoietin be used to prevent brain damage in cerebral malaria?". <i>Trends in Parasitology</i>. <b>25</b> (1): 30–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pt.2008.10.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pt.2008.10.002'" tppabs="https://doi.org/10.1016%2Fj.pt.2008.10.002" class="external text external">10.1016/j.pt.2008.10.002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19008152  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19008152'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19008152" class="external text external">19008152</a>.</cite></span></li><li id="cite_note-pmid21044627-11"> <span id="mw-reference-text-cite_note-pmid21044627-11" class="mw-reference-text"><cite id="CITEREFCoreHempelKurtzhalsPenkowa2011" class="citation journal cs1">Core A, Hempel C, Kurtzhals JA, Penkowa M (February 2011). "Plasmodium berghei ANKA: erythropoietin activates neural stem cells in an experimental cerebral malaria model". <i>Experimental Parasitology</i>. <b>127</b> (2): 500–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.exppara.2010.09.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.exppara.2010.09.010'" tppabs="https://doi.org/10.1016%2Fj.exppara.2010.09.010" class="external text external">10.1016/j.exppara.2010.09.010</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21044627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21044627'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21044627" class="external text external">21044627</a>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFMcKie2008" class="citation news cs1">McKie, Robin (2008-02-17). <a href="javascript:if(confirm('https://www.theguardian.com/science/2008/feb/17/medicalresearch.health1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.theguardian.com/science/2008/feb/17/medicalresearch.health1'" tppabs="https://www.theguardian.com/science/2008/feb/17/medicalresearch.health1" class="external text external">"Kidney drug could save children from malaria brain damage"</a>. London: The Guardian.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFBanksJumbeFarrellNiehoff2004" class="citation journal cs1">Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC (November 2004). "Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa". <i>European Journal of Pharmacology</i>. <b>505</b> (1–3): 93–101. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejphar.2004.10.035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejphar.2004.10.035'" tppabs="https://doi.org/10.1016%2Fj.ejphar.2004.10.035" class="external text external">10.1016/j.ejphar.2004.10.035</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15556141  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15556141'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15556141" class="external text external">15556141</a>.</cite></span></li><li id="cite_note-:0-14"> <span id="mw-reference-text-cite_note-:0-14" class="mw-reference-text"><cite id="CITEREFOhlssonAher2017" class="citation journal cs1">Ohlsson, Arne; Aher, Sanjay M. (16 November 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170" class="external text external">"Early erythropoiesis-stimulating agents in preterm or low birth weight infants"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>11</b>: CD004863. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD004863.pub5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD004863.pub5'" tppabs="https://doi.org/10.1002%2F14651858.CD004863.pub5" class="external text external">10.1002/14651858.CD004863.pub5</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486170" class="external text external">6486170</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29145693  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29145693'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29145693" class="external text external">29145693</a>.</cite></span></li><li id="cite_note-:1-15"> <span id="mw-reference-text-cite_note-:1-15" class="mw-reference-text"><cite id="CITEREFAherOhlsson2020" class="citation journal cs1">Aher, Sanjay M.; Ohlsson, Arne (11 February 2020). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632" class="external text external">"Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>2</b>: CD004865. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD004865.pub4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD004865.pub4'" tppabs="https://doi.org/10.1002%2F14651858.CD004865.pub4" class="external text external">10.1002/14651858.CD004865.pub4</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014632" class="external text external">7014632</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32048729  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32048729'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32048729" class="external text external">32048729</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text">R. Baselt, <i>Disposition of Toxic Drugs and Chemicals in Man</i>, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 547-549. 
</span></li><li id="cite_note-pmid17108342-17"> <span id="mw-reference-text-cite_note-pmid17108342-17" class="mw-reference-text"><cite id="CITEREFDrüekeLocatelliClyneEckardt2006" class="citation journal cs1">Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A (November 2006). "Normalization of hemoglobin level in patients with chronic kidney disease and anemia". <i>The New England Journal of Medicine</i>. <b>355</b> (20): 2071–84. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa062276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa062276'" tppabs="https://doi.org/10.1056%2FNEJMoa062276" class="external text external">10.1056/NEJMoa062276</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17108342  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17108342'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17108342" class="external text external">17108342</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070528103823/https://www.fda.gov/cder/drug/advisory/RHE2007.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070528103823/https://www.fda.gov/cder/drug/advisory/RHE2007.htm'" tppabs="https://web.archive.org/web/20070528103823/https://www.fda.gov/cder/drug/advisory/RHE2007.htm" class="external text external">"FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp)"</a>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cder/drug/advisory/RHE2007.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/drug/advisory/RHE2007.htm'" tppabs="https://www.fda.gov/cder/drug/advisory/RHE2007.htm" class="external text external">the original</a> on 2007-05-28<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-06-05</span></span>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070515034509/https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070515034509/https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm'" tppabs="https://web.archive.org/web/20070515034509/https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm" class="external text external">"Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA)"</a>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm'" tppabs="https://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm" class="external text external">the original</a> on 2007-05-15<span class="reference-accessdate">. Retrieved <span class="nowrap">2007-06-05</span></span>.</cite></span></li><li id="cite_note-urlMedWatch_-_2007_Safety_Information_Alerts-20"> <span id="mw-reference-text-cite_note-urlMedWatch_-_2007_Safety_Information_Alerts-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090409003452/https://www.fda.gov/MedWatch/safety/2007/safety07.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090409003452/https://www.fda.gov/MedWatch/safety/2007/safety07.htm'" tppabs="https://web.archive.org/web/20090409003452/https://www.fda.gov/MedWatch/safety/2007/safety07.htm" class="external text external">"Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)"</a>. <i>MedWatch - 2007 Safety Information Alerts</i>. U.S. Food and Drug Administration. 2008-01-03. Archived from <a href="javascript:if(confirm('https://www.fda.gov/medwatch/safety/2007/safety07.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/medwatch/safety/2007/safety07.htm#ESA2'" tppabs="https://www.fda.gov/medwatch/safety/2007/safety07.htm#ESA2" class="external text external">the original</a> on April 9, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-04-09</span></span>.</cite></span></li><li id="cite_note-urlwww.fda.gov__Procrit-21"> <span id="mw-reference-text-cite_note-urlwww.fda.gov__Procrit-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090118031036/https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090118031036/https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf'" tppabs="https://web.archive.org/web/20090118031036/https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf" class="external text external">"Procrit (Epoetin alfa) for injection"</a> <span class="cs1-format">(PDF)</span>. U.S. Food and Drug Administration. 2007-08-11. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf'" tppabs="https://www.fda.gov/cder/foi/label/2007/103234s5158lbl.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on January 18, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-04-09</span></span>.</cite></span></li><li id="cite_note-urlwww.fda.gov__Aranesp-22"> <span id="mw-reference-text-cite_note-urlwww.fda.gov__Aranesp-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090118031507/https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090118031507/https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf'" tppabs="https://web.archive.org/web/20090118031507/https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf" class="external text external">"Aranesp (darbepoetin alfa) for Injection"</a> <span class="cs1-format">(PDF)</span>. U.S. Food and Drug Administration. 2007-11-08. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf'" tppabs="https://www.fda.gov/cder/foi/label/2007/103951s5164lbl.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on January 18, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-04-09</span></span>.</cite></span></li><li id="cite_note-urlInformation_on_Erythropoiesis_Stimulating_Agents_(ESA)_(marketed_as_Procrit,_Epogen,_and_Aranesp)-23"> <span id="mw-reference-text-cite_note-urlInformation_on_Erythropoiesis_Stimulating_Agents_(ESA)_(marketed_as_Procrit,_Epogen,_and_Aranesp)-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/cder/drug/infopage/RHE/default.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/drug/infopage/RHE/default.htm'" tppabs="https://www.fda.gov/cder/drug/infopage/RHE/default.htm" class="external text external">"Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen, and Aranesp)"</a>. U.S. Food and Drug Administration. 2009-01-26<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-04-09</span></span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/drug-interactions/epoetin-alfa,epogen.html/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/drug-interactions/epoetin-alfa,epogen.html/'" tppabs="https://www.drugs.com/drug-interactions/epoetin-alfa,epogen.html/" class="external text external">Drug Interactions of Erythropoietin Alfa at Drugs.com</a></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFHardellWalkerWalhjaltFriedman2007" class="citation journal cs1">Hardell L, Walker MJ, Walhjalt B, Friedman LS, Richter ED (March 2007). "Secret ties to industry and conflicting interests in cancer research". <i>American Journal of Industrial Medicine</i>. <b>50</b> (3): 227–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fajim.20357  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fajim.20357'" tppabs="https://doi.org/10.1002%2Fajim.20357" class="external text external">10.1002/ajim.20357</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17086516  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17086516'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17086516" class="external text external">17086516</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFMaryann_Napoli2011" class="citation cs2">Maryann Napoli (October 5, 2011), <a href="javascript:if(confirm('https://web.archive.org/web/20120105140525/http://medicalconsumers.org/2011/10/05/whistleblowers-story-new-book-reviewed/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120105140525/http://medicalconsumers.org/2011/10/05/whistleblowers-story-new-book-reviewed/'" tppabs="https://web.archive.org/web/20120105140525/http://medicalconsumers.org/2011/10/05/whistleblowers-story-new-book-reviewed/" class="external text external"><i>Whistleblower's story: New book reviewed</i></a>, Center for Medical Consumers, archived from the original on January 5, 2012<span class="reference-accessdate">, retrieved <span class="nowrap">2012-02-12</span></span></cite><span class="cs1-maint citation-comment">CS1 maint: BOT: original-url status unknown (link)</span>| archive-url=
| archive-date=January 5, 2012</span></li><li id="cite_note-cbs-27"> <span id="mw-reference-text-cite_note-cbs-27" class="mw-reference-text"><cite id="CITEREFEdwards2009" class="citation news cs1">Edwards, Jim (August 17, 2009). <a href="javascript:if(confirm('http://www.cbsnews.com/8301-505123_162-42842558/drug-rep-in-3b-procrit-case-80-of-my-sales-were-medicare-fraud-carried-400k-in-cash/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cbsnews.com/8301-505123_162-42842558/drug-rep-in-3b-procrit-case-80-of-my-sales-were-medicare-fraud-carried-400k-in-cash/'" tppabs="http://www.cbsnews.com/8301-505123_162-42842558/drug-rep-in-3b-procrit-case-80-of-my-sales-were-medicare-fraud-carried-400k-in-cash/" class="external text external">"Drug Rep in $3B Procrit Case: "80% of My Sales Were Medicare Fraud"; Carried $400K in "Cash<span class="cs1-kern-right">"</span>"</a>. CBS news<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-02-12</span></span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit" class="external text external">"Binocrit EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal" class="external text external">"Epoetin Alfa Hexal EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/abseamed  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/abseamed'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/abseamed" class="external text external">"Abseamed EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/rn/113427-24-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/rn/113427-24-0'" tppabs="https://druginfo.nlm.nih.gov/drugportal/rn/113427-24-0" class="external text external">"Epoetin alfa"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5" class="external text external">"Epogen- epoetin alfa solution"</a>. <i>DailyMed</i>. 25 July 2018.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374" class="external text external">"Retacrit- epoetin alfa-epbx injection, solution"</a>. <i>DailyMed</i>. 29 January 2020.</cite></li>
<li><a href="javascript:if(confirm('http://www.medicinenet.com/epoetin_alfa/article.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicinenet.com/epoetin_alfa/article.htm'" tppabs="http://www.medicinenet.com/epoetin_alfa/article.htm" class="external text external">MedicineNet.com</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>